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Abstract: A series of novel fusidic acid (FA) derivatives was synthesized by replacing 
the carboxylic acid group with various ester and amide groups and evaluated in vitro for 
their antiplasmodial activity against the chloroquine-sensitive NF54 and multidrug-
resistant K1 strains of the malarial parasite Plasmodium falciparum. Most of these 
derivatives showed a 4-49 and 5-17 fold increase in activity against NF54 and KI strains, 
respectively, as compared to FA and had a good selectivity index. These derivatives are 
stable over the incubation period and do not appear to be prodrugs of fusidic acid.  
 
Malaria persists as a major public health problem, resulting in 214 million cases and 
causing 438,000 deaths worldwide in 2015.1 The disease, transmitted by female Anopheles 
mosquitoes, is caused by five different species of the protozoan Plasmodium parasite, namely: 
P.falciparum, P.vivax, P.malariae, P.ovale, and P.knowlesi that infect and destroy red blood 
cells leading to high fever, anaemia, cerebral malaria, and possibly death. Of these, P. 
falciparum is the most lethal as well as the most prevalent in sub-Saharan Africa and is 
responsible for high mortality rates especially amongst young children and pregnant women. 
As there is no available vaccine, the control of the disease relies largely on the use of bed nets, 
other individual protection against mosquito bites, and the successful drug treatment of infected 
patients.2 The rapid development of drug resistance has compromised the use of previously 
effective drugs such as chloroquine, sulfadoxine/pyrimethamine and artemisinin.3,4 In this 
context, the discovery and development of new molecules with novel mechanisms of action 
and no cross-resistance to current drugs is necessary. 
 
Nature has always been a rich source of potential antimalarial agents. Two of the most effective 
antimalarial drugs quinine and artemisinin are natural products isolated from Cinchona 
officinalis and Artemisia annua, respectively, and many of the synthetic antimalarial drugs are 
analogues of these two natural products.5–8 Fusidic acid (FA) (Figure 1) is a steroid-based, 
narrow spectrum bacteriostatic antibiotic belonging to a family of naturally occurring 
antibiotics, the fusidanes, which have a tetracyclic ring system with a unique chair-boat-chair 
conformation. It was first isolated from the fungus Fusidium coccineum in 1960 and has been 
in clinical use since 1962 for the treatment of skin, bone and joint infections caused by 
Staphylococcus aureus as well as against several other Gram-positive species.9–11 The in vitro 
MIC50 of FA against most gram-positive bacteria lies between 0.1µM – 1µM.12–14 Its proposed 
mechanism of action (MoA) involves inhibition of bacterial protein synthesis by locking 
elongation factor-G (EF-G) on the ribosome with Guanosine 5′-diphosphate (GDP) in a post-
translocational state.15,16 The clinical value of FA is attributed to its excellent tissue 
distribution, low degree of toxicity and allergic reactions, excellent oral bioavailability, and the 
absence of cross-resistance with other clinically used antibiotics.17,18 
 
 
 
 
 
 
Figure 1. Structure of fusidic acid 
FA has also been reported to have in vitro antiplasmodial activity, with a reported IC50 
of about 50µM against chloroquine-sensitive P. falciparum line D10.19,20 Its MoA has been 
proposed to be through inhibition of plasmodial EF-Gs, which harbour bacteria-like metabolic 
processes and are localised within the parasite’s mitochondria and the relict apicoplast.20,21 
We have been exploring the antiplasmodial potential of FA and its derivatives. 
Recently, we identified a number of FA derivatives with better (2-35 fold relative to FA) 
antiplasmodial activity by replacing its carboxylic acid with various bioisosteres.22 In the 
present investigation, we report the synthesis and biological evaluation of novel aliphatic as 
well as aromatic ester and amide analoguesof FA. 
 
 
The compounds synthesized for this study are presented in Table 1 with the 
corresponding synthetic routes outlined in Scheme 1. Target compounds were synthesized 
following a straightforward synthetic route involving a single step from commercially available 
fusidic acid 1 (Scheme 1). Aryl esters of fusidic acid 2a-o were obtained in moderate to good 
yield (38-89%, Table 1) by reacting 1 with corresponding alcohols (ROH) using N,N’-
dicyclohexylcarbodiimide (DCC) as a coupling agent in the presence of a catalytic amount of 
4-dimethylaminopyridine (DMAP) in dichloromethane. Aliphatic ester 2p-u were obtained 
through 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI)-mediated coupling of 1 with 
corresponding alcohols in relatively poor yield (9-37%, Table 1). EDCI mediated coupling of 
1 with corresponding amines on the other hand, afforded aromatic (2v) and aliphatic (2w-y) 
amide derivatives in moderate to good yields (31-73%, Table 1). All the target compounds 
were purified using column chromatography and fully characterized by a range of analytical 
and spectroscopic techniques (see ESI†). 
 
 
 
 
 
 
 
Scheme 1. Reagents andreaction conditions: (a) ROH (1.3 equiv.), DCC (1.3 equiv.), DMAP, 
DCM (15 ml), 2 h, 25 ºC; (b) ROH/RNH2 (1.2 equiv.), EDCI (2.5 equiv.), DMAP (2.5 equiv.), 
DCM (6 ml), 12 h, 25 ºC. 
 
The synthesized compounds were evaluated for their in vitro antiplasmodial activity 
against the chloroquine-sensitive NF54 strain, using the lactate dehydrogenase assay, and the 
multidrug-resistant K1 strain, using the modified [3H]hypoxanthine incorporation assay.23,24 
Chloroquine and artesunate were used as the reference drugs in all the experiments. 
Compounds were also evaluated for cytotoxicity against a mammalian cell-line, Chinese 
Hamster Ovarian (CHO) cells.   
The in vitro antiplasmodial activity and cytotoxicity data as indicated by their IC50 
values is summarized in Table 1. Most of these analogues were equipotent against both strains 
(NF54 and K1). The IC50 of FA against NF54 and K1strains was 59.0 and 19.0 µM, 
respectively. 21 out of 25 compounds (2a-r, 2v-x, Table 1) displayed superior potency 
compared to FA against both NF54 (4-49 fold) and K1(5-17 fold) strains with IC50 ≤ 13.4 µM 
and ≤ 4.0 µM, respectively.  
The potencies of 2a-o indicated that aromatic ester derivatives were well tolerated. 
Unsubstituted aromatic ester (2a, Table 1) as well as ester derivatives substituted with electron-
withdrawing groups (EWG), fluoro (2b), chloro (2c) and bromo (2d) in the para-position 
resulted in 20-28-fold and 12-14-fold enhancement in antiplasmodial activity relative to FA 
against both P.falciparum NF54 and K1. Varying the position of the substituent from para- to 
meta-on the phenyl ring did not have a significant effect on antiplasmodial activity against both 
the strains (2b, 2c and 2d vs 2e, 2f and 2g, respectively) as all of these derivatives retained 
comparable activity. Likewise, introduction of an electron-donating group (EDG), -OMe in the 
meta-position (2h) resulted in similar activity values (Table 1). Further, disubstituted 
derivatives (2i-n) retained good antiplasmodial activity. Among dichloro-substituted 
derivatives (2i-k), 3,5-disubstituted ester analogue (2j) was found to have superior activity 
against both strains (NF54, IC50 = 2.0 µM; K1, IC50 = 1.1 µM) in comparison to its 3,4-
disubstituted (2i) and 2,4-disubstituted (2k) analogues. The activity of 4-chloro-substituted 
derivative (2c) was also compared with its regioisomer, 3-chloro (2f) as well as the 3,4-dichloro 
(2i), 3,5-dichloro (2j) and 2,4-dichlorosubstituted (2k) ester derivatives; compound 2f was 
found to be the most active amongst them with an IC50 value of 1.4μM and 1.2μM against 
NF54 and K1 strain, respectively. The comparison of 3,5-dichlorosubstituted (2j) analogue 
with 3,5-difluorosubstituted (2l) ones revealed higher activity for the former. Ester analogues 
of fusidic acid having the phenyl ring disubstituted with electron releasing -Me group at the 
2,5- (2m, NF54, IC50 3.0 µM; KI, IC50 1.4 µM) and 2,4-positions (2n, NF54, IC50 2.4 µM; KI, 
IC50 1.4 µM) also retained potency against both strains. It can be concluded from these results 
that the electronic properties of the substituents do not have a significant impact on the 
antiplasmodial activity of these compounds. Attempts at replacing the phenyl ring with a 
naphthyl group yielded ester analogue (2o) having similar activity. The effect of aliphatic esters 
with varying carbon chain lengths on antiplasmodial activity was also established wherein it 
was observed that an increase in carbon chain length decreased the activity. Although 
derivatives 2p-r demonstrated superior antiplasmodial activity (NF54, IC50 3.4-4.6 µM; KI, 
IC50 1.5-2.2 µM) as compared to fusidic acid, lengthening of the alkyl chain (2s-t, Table 1), 
diminished their corresponding activities. All these aryl and alkyl ester derivatives (2a-u) were 
also tested for cytotoxicity and were found to be non-cytotoxic, as indicated by their high IC50 
values against CHO cell lines as well as their high selectivity index values (Table 1). Replacing 
an ester with an amide functionality seemed to have no effect on activity as aromatic amide 
derivative also retained the antiplasmodial activity (2v vs 2a, Table 1). However, long chain 
alkyl amide derivatives were found to be active, in striking contrast to their ester counterparts 
(2w and 2x vs 2s and 2t, respectively, Table 1). Amide derivatives also displayed favourable 
toxicity profiles as evident from their high SI values.  
Table 1.  Yields, in vitro antiplasmodial activity of compounds against NF54 and K1 strain of 
P. falciparum, cytotoxicity against CHO cell lines and selectivity index. 
 
 
 
Compound X R 
Yield 
(%) 
Antiplasmodial  
activity 
Cytotoxicity 
(CHO) IC50, 
μM 
 
SIa NF54 
IC50, µM 
K1 
IC50, µM 
Fusidic acid    59.0 19.0 >194 >3 
2a O 
 
55 2.4 1.4 99.4 41 
2b O 
 
38 2.9 1.4 79.4 27 
2c O 
 
89 2.3 1.4 71.6 31 
2d O 
 
52 2.1 1.6 95.3 45 
2e O 
 
88 2.6 2.0 89.4 34 
2f O 
 
61 1.4 1.2 87.7 63 
2g O 
 
51 2.6 1.6 98.3 38 
2h O 
 
88 1.8 1.3 86.4 48 
2i O 
 
54 3.6 2.2 95.0 26 
2j O 
 
82 2.0 1.1 81.9 41 
2k O 
 
72 3.5 1.7 99.7 28 
2l O 
 
61 4.7 ND 96.7 21 
2m O 
 
43 3.0 1.4 102.9 34 
2n O 
 
42 2.4 1.4 98.9 41 
2o O 
 
52 3.2 1.7 >155 >48 
2p O CH2CH3 9 3.4 2.2 65.5 19 
2q O (CH2)3CH3 37 2.9 1.5 37.4 13 
2r O (CH2)7CH3 19 4.6 1.6 92.4 20 
2s O (CH2)11CH3 21 >100 >14.6 >146 ND 
2t O (CH2)13CH3 9 >100 >14.0 >140 ND 
2u O (CH2)15CH3 29 >100 >13.5 >135 ND 
2v NH 
 
31 1.2 1.4 89.2 74 
2w NH (CH2)11CH3 51 1.2 1.5 >146 >122 
2x NH (CH2)13CH3 71 13.4 4.0 >140 >10 
2y NH (CH2)15CH3 73 >100 >13.5 >135 ND 
Artesunate    0.0093 0.0026   
Chloroquine    0.0256 0.036    
Emetine      0.178  
ND = not determined. aSI (selectivity index) = IC50CHO/IC50NF54. 
Plasmodial parasites are known to possess esterase enzymes which can hydrolyse 
prodrugs to their active forms.25 We therefore investigated whether these compounds were 
being hydrolysed to FA during incubation. The experiment was designed with the same setup 
as the IC50 determination, but with sampling at various time points during the incubation (see 
ESI†). FA was not detected in any of the incubations and the relative compound concentration 
remained constant throughout the 48-hour incubation. This suggests that these derivatives are 
not prodrugs of FA but are actually active in their original form. This finding is in line with our 
previous work on FA bioisosteres where we observed better antiplasmodial activity with the 
more lipophilic carboxylic acid bioisosteres. It also confirms our previous finding that a free 
carboxylic acid group is not essential for antiplasmodial activity. This is distinct from the 
antibacterial activity of FA analogues where activity is lost on substitution of the acid, and 
suggests differences in the targets and/or MoA between bacteria and plasmodia. 26,27 
In conclusion, a series of novel FA derivatives have been synthesized by replacing the 
carboxylic acid group with aliphatic as well as aromatic ester and amide groups, and evaluated 
in vitro for their antiplasmodial activity against NF54 and K1 strains of P. falciparum. Almost 
all of these analogues exhibited improved antiplasmodial activity relative to FA against both 
strains with good selectivity index values. The enhanced antiplasmodial activity substantiates 
the insignificance of a free carboxylic group for antiplasmodial activity. In addition, these 
derivatives were stable over the incubation period and were not converted to fusidic acid under 
the incubation conditions used and are therefore unlikely to act as prodrugs. Overall this work 
demonstrates the potential of FA as a promising novel antimalarial template. 
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